Back to search
FDAFDA · Food and drugs·Recall number D-0099-2026

HADLIMA (adalimumab-bwwd) injection, 40mg/0.8 mL, 2 Single-dose Prefilled Syringes per carton, Rx only, Manufactured for: Organon LLC, a subsidiary of ORGANON & Co, Jersey City, NJ 07302, Manufactured by: SAMSUN BIOEPIS Co., Ltd, Incheon, Republic of Korea, NDC 78206-183-01.

Published November 5, 2025 · Recall initiated: October 10, 2025

Summary

FDA records drug Class II recall D-0099-2026, published November 5, 2025 and initiated October 10, 2025. Recalling firm: Samsung Bioepis Co., Ltd.; Status: Ongoing; Reported quantity: 5,518 packs (11,036 Syringes) 2 syringes/carton); Lot: Lot: F2505017, Expiry: 24-Jan-2027. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Samsung Bioepis Co., Ltd.
Distributor
Distributed only to one warehouse in NJ. with no further distribution
Lot
Lot: F2505017, Expiry: 24-Jan-2027
Risk classification
Class II
Area (FDA)
drug
Country
Korea (the Republic of)

Related recalls

Questions about this recall

Was HADLIMA (adalimumab-bwwd) injection, 40mg/0.8 mL, 2 Single-dose Prefilled Syringes per carton, Rx only, Manufactured for: Organon LLC, a subsidiary of ORGANON & Co, Jersey City, NJ 07302, Manufactured by: SAMSUN BIOEPIS Co., Ltd, Incheon, Republic of Korea, NDC 78206-183-01. recalled?

Yes. FDA published recall D-0099-2026 on November 5, 2025. Reported hazard: Lack of Assurance of Sterility.

What should I do if I have this product?

Voluntary: Firm initiated · Letter